FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 101 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... October 24, 2025 FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory... April 20, 2021 The Cancer Moonshot: A Midpoint Progress Update January 11, 2021 Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar... May 5, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... The Doctor Will See You Now…On the Screen Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following...
